Havrix Za Otroke (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Za Otroke is indicated for the prevention of hepatitis A infection in individuals for whom active immunization is appropriate.

• Administration to children as part of routine childhood vaccination programs.
• Use in travelers to regions where hepatitis A is endemic.
• Immunization of individuals at increased risk due to occupational exposure (e.g., food handlers, healthcare workers).
• Boosting immunity in persons who have previously received a hepatitis A vaccine series.
• Providing protection for outbreak control in community settings.
• Administration as a two-dose schedule, with the second dose given 6 to 12 months after the first to achieve long‑term immunity.

The safety profile of Havrix Za Otroke reflects typical reactions observed with inactivated viral vaccines.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Headache.
• Fatigue or mild malaise.
• Mild nausea.
• Transient joint pain.
• Mild rash at the injection site.
• Temporary loss of appetite.
• Mild dizziness or light‑headedness.

Serious

• Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, rash, or swelling of the face and throat.
• Guillain‑Barré syndrome, a rare neurological condition presenting with muscle weakness.
• Thrombocytopenia with unexpected bruising or bleeding.
• Seizures (rare) occurring within days after vaccination.
• Autoimmune hepatitis, a rare inflammatory liver condition presenting with elevated liver enzymes.

Precautions for Havrix Za Otroke focus on patient history, immune status, and proper administration techniques.

• Verify that the individual has not previously received a hepatitis A vaccine dose within the past 6 months.
• Defer vaccination in persons with known severe allergic reaction to any component of the product, including algeldrate.
• Postpone administration in individuals with acute moderate or severe illness until recovery.
• Use with caution in immunocompromised patients, as response may be reduced.
• Counsel pregnant or breastfeeding women that safety data are limited and vaccination should be considered based on risk assessment.
• Ensure correct intramuscular injection technique to minimize local reactions.

Havrix Za Otroke may interact with other agents that affect immune response or increase the risk of hypersensitivity.

Avoid

• Concurrent administration with live viral vaccines (e.g., measles, mumps, rubella) should be avoided, as immune interference may reduce efficacy.
• Simultaneous use of immunoglobulin products or blood products containing anti‑hepatitis A antibodies should be avoided because they can neutralize the vaccine antigen.

Use with caution

• Administration with other inactivated vaccines (e.g., diphtheria‑tetanus‑pertussis) is permissible but monitor for increased local reactions.
• Use in patients receiving immunosuppressive therapy (e.g., corticosteroids, biologics) may result in diminished antibody response; assess serologic protection.
• Co‑administration with antipyretics (e.g., acetaminophen) may mask fever, a common post‑vaccination sign; consider timing.